CaMKII as a target for arrhythmia suppression-Reference-Cited by-同舟云学术

CaMKII as a target for arrhythmia suppression

Published:2017-08 Issue: Volume:176 Page:22-31
ISSN:0163-7258
Container-title:Pharmacology & Therapeutics
language:en
Short-container-title:Pharmacology & Therapeutics

Author:

Mustroph Julian,Neef Stefan,Maier Lars S.

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference128 articles.

1. Ca2+/calmodulin-dependent protein kinase modulates cardiac ryanodine receptor phosphorylation and sarcoplasmic reticulum Ca2+ leak in heart failure;Ai;Circ Res,2005

2. KN-93, an inhibitor of multifunctional Ca++/calmodulin-dependent protein kinase, decreases early afterdepolarizations in rabbit heart;Anderson;J Pharmacol Exp Ther,1998

3. Overview of basic mechanisms of cardiac arrhythmia;Antzelevitch;Card Electrophysiol Clin,2011

4. The δ isoform of CaM kinase II is required for pathological cardiac hypertrophy and remodeling after pressure overload;Backs;Proc Natl Acad Sci,2009

5. Regulation of signal transduction by protein targeting: the case for CaMKII;Bayer;Biochem Biophys Res Commun,2001

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dapagliflozin: A sodium–glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced atrial fibrillation by regulating atrial electrical and structural remodeling;European Journal of Pharmacology;2024-09

2. Ruxolitinib as a CaMKII inhibitor for treatment of cardiac arrhythmias: Applications and prospects;Heart Rhythm;2024-08

3. USP38 exacerbates pressure overload-induced left ventricular electrical remodeling;Molecular Medicine;2024-06-27

4. Empagliflozin, a sodium‐glucose cotransporter inhibitor enhancing mitochondrial action and cardioprotection in metabolic syndrome;Journal of Cellular Physiology;2024-05-19

5. Drug-induced atrial fibrillation. A narrative review of a forgotten adverse effect;Pharmacological Research;2024-02